• STAT+: Pharmalittle: Biogen defends its controversial Alzheimer's drug; critics pan Pfizer plan for Covid-19 shot production in Africa

    13 days ago - By STAT

    Everyone, and how are you today? A shiny sun and delightful breeze are enveloping the Pharmalot campus this morning, where the short person has left for gainful summer employment and the official mascot is happily snoozing in his corner. As for us, we are staring at the intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing....
    Biogen mounted a vigorous defense of...
    Read more ...

     

  • Biogen mounts defense of its Alzheimer's drug, saying ‘misinformation' is fueling controversy

    13 days ago - By STAT

    Biogen on Thursday mounted a vigorous defense of its controversial Alzheimer's drug, Aduhelm, with the company's head of research and development releasing an open letter to the Alzheimer's community that took direct aim at critics of approval.
    Al Sandrock, the R&D chief and an architect of many of Biogen's successes, wrote that the purpose of the letter was to correct “misinformation” about the drug.
    Read more ...